Tumor budding in tumor invasive front predicts prognosis and survival of patients with esophageal squamous cell carcinomas receiving neoadjuvant chemotherapy

Cancer

Volumn 115, Issue 14, 2009, Pages 3324-3334

  Miyata, Hiroshi ^a   Yoshioka, Akiko ^a   Yamasaki, Makoto ^a   Nushijima, Yoichiro ^a   Takiguchi, Shuji ^a   Fujiwara, Yoshiyuki ^a   Nishida, Toshiro ^a   Mano, Masayuki ^b   Mori, Masaki ^a   Doki, Yuichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA NATIONAL HOSPITAL   (Japan)

Author keywords

Esophageal carcinoma; Histologic evaluation; Neoadjuvant chemotherapy; Prognostic factors; Tumor budding

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER INVASION; CANCER PATIENT; CELL BUDDING; CLINICAL EVALUATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; LYMPHATIC SYSTEM; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SURVIVAL; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DOXORUBICIN; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 68549140124     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24390     Document Type: Article

References (44)

1. Muller JM, Erasmi H, Stelzner M, Zieren U, Pichlmaier H. Surgical therapy of oesophageal carcinoma. Br J Surg. 1990;77:845-857.
2. Refaely Y, Krasna MJ. Multimodality therapy for esophageal cancer. Surg Clin North Am. 2002;82:729-746.
3. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335:462-467. (Pubitemid 26269945)
4. Gebski V, Burmeister B, Smithers BM, et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8:226-234. (Pubitemid 46291702)
5. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26:1086-1092.
6. Law S, Fok M, Chow S, Chu KM, Wong J. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg. 1997;114:210-217. (Pubitemid 27364211)
7. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomized controlled trial. Lancet. 2002;359:1727-1733.
8. Yano M, Takachi K, Doki Y, et al. Preoperative chemotherapy for clinically node-positive patients with squamous cell carcinoma of the esophagus. Dis Esophagus. 2006;19: 158-163. (Pubitemid 43756662)
9. Ancona E, Ruol A, Santi S, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long-term survival of patients with respectable esophageal squamous cell carcinoma. Cancer. 2001;91: 2165-2174.
10. Urschel JD, Vasan H, Blewett CJ. A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for respectable esophageal cancer. Am J Surg. 2002;183:274-279. (Pubitemid 34273984)
11. Hilgenberg AD, Carey RW, Wilkins EW Jr, Choi NC, Mathisen DJ, Grrillo HC. Preoperative chemotherapy, surgical resection, and selective post-operative therapy for squamous cell carcinoma of the esophagus. Ann Thorac Surg. 1988;45:357-363. (Pubitemid 18097321)
12. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Cancer. 1994;73:2680-2686.
13. Chang F, Deere H, Mahadeva U, George S. Histopathologic examination and reporting of esophageal carcinomas following preoperative neoadjuvant therapy: practical guidelines and current issues. Am J Clin Pathol. 2008;129:252-262. (Pubitemid 352029316)
14. Berger AC, Farma J, Scott WJ, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 2005;23:4330-4336. (Pubitemid 46207006)
15. Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005;103:1347-1355.
16. Schneider PM, Baldus SE, Metzger R, et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer. Implication for response classification. Ann Surg. 2005;5:684-692.
17. Brücher BL, Becker K, Lordick F, et al. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer. 2006;106:2119-2127. (Pubitemid 43673232)
18. Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98: 1521-1530. (Pubitemid 37151509)
19. Japanese Societyfor Esophageal Diseases. Guidelines for the Clinical and Pathologic Studies on Carcinoma of the Esophagus. 10th ed. Tokyo: Kanehara Syuppan; 2007.
20. Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC. Tumor 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology. 2002;40:127-132.
21. Morodomi T, Isomoto H, Shirouzu K, Kakegawa K, Irie K, Morimatsu M. An index for estimating the probability of lymph node metastasis in rectal cancers-lymph node metastasis and the histopathology of actively invasive regions of cancer. Cancer. 1989;63:539-543. (Pubitemid 19038471)
22. Hase K, Shatncy C, Johnson D, Trollope M, Vierra M. Prognostic value of tumor 'budding' in patients with colorectal cancer. Dis Colon Rectum. 1993;36:627-635.
23. Roh MS, Lee JI, Choi PJ. Tumor budding as a useful prognostic marker in esophageal squamous cell carcinoma. Dis Esophagus. 2004;17:333-337. (Pubitemid 40123811)
24. Koike M, Kodera Y, Itoh Y, et al. Multivariate analysis of the pathologic features of esophageal squamous cell cancer: tumor budding is a significant independent prognostic factor. Ann Surg Oncol. 2008;15:1977-1982.
25. Miyata H, Doki Y, Shiozaki H, et al. CDC25B and p53 are independently implicated in radiation sensitivity for human esophageal cancers. Clin Cancer Res. 2000;6:4859-4865. (Pubitemid 32110430)
26. Swisher SG, Erasmus J, Masih M, et al. 2-flioro-2-deoxy-d-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer. 2004;101:1776-1785. (Pubitemid 39314740)
27. Downey RJ, Akhurst T, Ilson D, et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol. 2003;21:428-432. (Pubitemid 46606470)
28. Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2006;24:4692-4698. (Pubitemid 46646244)
29. Makino T, Doki Y, Miyata H, et al. Use of F-fluorodeoxy-glucose-positron emission tomography to evaluate responses to neo-adjuvant chemotherapy for primary tumor and lymph node metastasis in esophageal squamous cell carcinoma. Surgery. 2008;144:793-802.
30. Lahdesmaki H, Hao X, Sun B, et al. Distinguishing key biological pathways between primary breast cancers and their lymph node metastases by gene function-based clustering analysis. Int J Oncol. 2004;24:1589-1596.
31. Varambally S, Yu J, Rhodes DR, et al. Integrated genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell. 2005;8:393-406. (Pubitemid 41579834)
32. Stoecklein NH, Hosch SB, Bezler M, et al. Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell. 2008;13:441-453. (Pubitemid 351609446)
33. Lerut T, DeKeyn P, Coosemsms W, Van Raemdonck D, Scheys I, LeSaffre E. Surgical strategies in esophageal carcinoma with emphasis on radical lymphadenectomy. Ann Surg. 1992;216:583-590.
34. Brücher BL, Stein HJ, Werner M, Siewert JR. Lymphatic vessel invasion is an independent prognostic factor in patients with esophageal squamous cell carcinoma. Cancer. 2001;92:2228-2233.
35. Akiyama H, Tsurumaru M, Udagawa H, Kajiyama Y. Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg. 1994;220:364-373. (Pubitemid 24313229)
36. Imdahl A, Jenkner J, Ihling C, Ruckauer K, Farthmann EH. Is MIB-1 proliferation index a predictor for response to neoadjuvant therapy in patients with esophageal cancer? Am J Surg. 2000;179:514-520.
37. Beardsmore DM, Verbeke CS, Davies CL, Guillou PJ, Clark GW. Apoptotic and proliferative indexes in esophageal cancer: predictors of response to neoadjuvant therapy apoptosis and proliferation in esophageal cancer. J Gastrointest Surg. 2003;7:77-86.
38. Lee J, Im YH, Lee SH, et al. Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer. Cancer Chemother Pharmacol. 2008;61:569-577.
39. Assersohn L, Salter J, Powles TJ, et al. Studies of the potential utility of Ki-67 as a predictive molecular marker of clinical response in primary breast cancer. Breast Cancer Res Treat. 2003;82:113-123. (Pubitemid 37476011)
40. Chang J, Ormerod M, Powles TJ, Allred DC, Ashley SE, Dowsett M. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer. 2000;89:2145-2152.
41. Prall F, Ostward C. High-degree tumor budding and podia-formation in sporadic colorectal carcinomas with K-ras gene mutations. Hum Pathol. 2007;38:1696-1702. (Pubitemid 47589093)
42. Yang Li, Huang J, Ren X, et al. Abrogation of TGFb signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell. 2008;13:23-35. (Pubitemid 350309741)
43. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumor stroma promote breast cancer metastasis. Nature. 2007;449:557-565.
44. Kitamura T, Kometani K, Hashida H, et al. SMAD4-deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion. Nat Genet. 2007;39:467-475. (Pubitemid 46514777)